The Short-term Opioid Withdawal Using Buprenorphine (Bup Detox) Blending Team designed a training package to instruct treatment providers on the administration of a unique,13-day Buprenorphine taper intervention for opioid dependent patients. Research conducted in both inpatient and outpatient settings by the NIDA Clinical Trials Network demonstrated that, in contrast with the clonidine treatment group, patients receiving Buprenorphine provided more opioid-negative urine samples upon completion of the intervention. This training assumes some basic prior information about what Buprenorphine is and how it is used.
To obtain an overview of the Buprenorphine Treatment Blending product, download the brochure.
Blending Product Materials (download now!)
Bup Detox Blending Team Members
Thomas Freese, Ph.D. – Pacific Southwest ATTC (Chair)
Beth Rutkowski, M.P.H. – Pacific Southwest ATTC
Kay Gresham-Morrison, LCSW, ACSW – Southeast ATTC
Susan Storti, Ph.D., RN – ATTC of New England